A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT ID: NCT06952504
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
1123 participants
INTERVENTIONAL
2025-05-22
2032-05-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* EC is a type of cancer that starts in the tissues inside the uterus (womb)
* pMMR indicates that certain normal proteins are present in the cancer cells
* Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery
* Recurrent means the cancer came back after surgery
Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells.
The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Maintenance Treatment Arm A: Pembrolizumab + Sacituzumab Tirumotecan
During the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin area under the curve (AUC) 5 (mg/mL/min), and paclitaxel 175 mg/m2 or docetaxel 75 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months).
During the Maintenance Treatment Phase, participants receive sac-TMT 4 mg/kg on Days 1, 15, and 29 of each 6-week cycle and pembrolizumab 400 mg on Day 1 of each 6-week cycle for up to 14 cycles (up to approximately 19 months).
Pembrolizumab
Intravenous (IV) Infusion
Carboplatin
During the Induction Phase, participants receive carboplatin AUC 5 (mg/mL/min) on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Paclitaxel
During the Induction Phase, participants receive paclitaxel 175 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Docetaxel
During the Induction Phase, participants may receive docetaxel (in place of paclitaxel) 75 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Sacituzumab Tirumotecan
IV Infusion
Maintenance Treatment Arm B: Pembrolizumab Monotherapy
During the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin AUC 5 (mg/mL/min), and paclitaxel 175 mg/m2 or docetaxel 75 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months).
During the Maintenance Treatment Phase, participants receive pembrolizumab 400 mg on Day 1 of each 6-week cycle for up to 14 cycles (up to approximately 19 months).
Pembrolizumab
Intravenous (IV) Infusion
Carboplatin
During the Induction Phase, participants receive carboplatin AUC 5 (mg/mL/min) on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Paclitaxel
During the Induction Phase, participants receive paclitaxel 175 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Docetaxel
During the Induction Phase, participants may receive docetaxel (in place of paclitaxel) 75 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Subsequent Treatment Arm A: Pembrolizumab + Sacituzumab Tirumotecan
During the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin AUC 5 (mg/mL/min), and paclitaxel 175 mg/m2 or docetaxel 75 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months).
During the Subsequent Treatment Phase, participants receive sac-TMT 4 mg/kg on Days 1, 15, and 29 of each 6-week cycle until discontinuation criteria is met and pembrolizumab 400 mg on Day 1 of each 6-week cycle for up to 14 cycles (up to approximately 19 months).
Pembrolizumab
Intravenous (IV) Infusion
Carboplatin
During the Induction Phase, participants receive carboplatin AUC 5 (mg/mL/min) on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Paclitaxel
During the Induction Phase, participants receive paclitaxel 175 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Docetaxel
During the Induction Phase, participants may receive docetaxel (in place of paclitaxel) 75 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Sacituzumab Tirumotecan
IV Infusion
Subsequent Treatment Arm B: Sacituzumab Tirumotecan Monotherapy
During the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin AUC 5 (mg/mL/min), and paclitaxel 175 mg/m2 or docetaxel 75 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months).
During the Subsequent Treatment Phase, participants receive sac-TMT 4 mg/kg on Days 1, 15, and 29 of each 6-week cycle until discontinuation criteria is met.
Carboplatin
During the Induction Phase, participants receive carboplatin AUC 5 (mg/mL/min) on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Paclitaxel
During the Induction Phase, participants receive paclitaxel 175 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Docetaxel
During the Induction Phase, participants may receive docetaxel (in place of paclitaxel) 75 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Sacituzumab Tirumotecan
IV Infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pembrolizumab
Intravenous (IV) Infusion
Carboplatin
During the Induction Phase, participants receive carboplatin AUC 5 (mg/mL/min) on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Paclitaxel
During the Induction Phase, participants receive paclitaxel 175 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Docetaxel
During the Induction Phase, participants may receive docetaxel (in place of paclitaxel) 75 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Sacituzumab Tirumotecan
IV Infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has radiographically evaluable disease, with measurable Stage III or either measurable or non-measurable Stage IV or recurrent disease per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1), as assessed by the investigator.
* Has received no prior systemic therapy for endometrial carcinoma except the following conditions as pre-specified by the protocol: 1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy in the setting of curative-intent, prior radiation with or without radiosensitizing chemotherapy if \>2 weeks before the start of induction treatment, or prior hormonal therapy for treatment of endometrial carcinoma that was discontinued ≥1 week before the start of induction treatment
Exclusion Criteria
* Has endometrial carcinoma of any histology that is mismatch repair deficient (dMMR)
* Is a candidate for curative-intent surgery or curative-intent radiotherapy at the time of enrollment
* Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
* Human Immunodeficiency Virus-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
* Received prior therapy in any setting with any of the following: anti-programmed cell death 1 protein, anti-programmed cell death ligand 1, anti-programmed cell death ligand 2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor; trophoblast cell surface antigen 2-targeted antibody drug conjugate; or topoisomerase I inhibitor-containing antibody drug conjugate
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of South Alabama, Mitchell Cancer Institute ( Site 6033)
Mobile, Alabama, United States
Alaska Women's Cancer Care ( Site 6036)
Anchorage, Alaska, United States
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020)
Orange, California, United States
MedStar Washington Hospital Center ( Site 5005)
Washington D.C., District of Columbia, United States
Florida Cancer Specialists - South ( Site 7003)
Fort Myers, Florida, United States
Mount Sinai Cancer Center ( Site 6031)
Miami Beach, Florida, United States
Florida Cancer Specialists - North ( Site 7002)
St. Petersburg, Florida, United States
Florida Cancer Specialists East ( Site 7001)
West Palm Beach, Florida, United States
St. Joseph's/Candler Health System ( Site 6021)
Savannah, Georgia, United States
Parkview Research Center ( Site 6008)
Fort Wayne, Indiana, United States
Women's Cancer Care ( Site 6010)
Covington, Louisiana, United States
TRIALS 365 ( Site 6005)
Shreveport, Louisiana, United States
Maine Medical Center - Scarborough Campus ( Site 6042)
Scarborough, Maine, United States
Minnesota Oncology Hematology, PA ( Site 8003)
Minneapolis, Minnesota, United States
St. Dominic's Hospital ( Site 5004)
Jackson, Mississippi, United States
Holy Name Medical Center ( Site 6011)
Teaneck, New Jersey, United States
University of New Mexico Comprehensive Cancer Center ( Site 6046)
Albuquerque, New Mexico, United States
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 6055)
Mineola, New York, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6004)
New York, New York, United States
FirstHealth of the Carolinas ( Site 6037)
Pinehurst, North Carolina, United States
Miami Valley Hospital South ( Site 6014)
Centerville, Ohio, United States
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6047)
Tulsa, Oklahoma, United States
St. Luke's University Health Network ( Site 6041)
Bethlehem, Pennsylvania, United States
Hospital of the University of Pennsylvania ( Site 5007)
Philadelphia, Pennsylvania, United States
Hospital of the University of Pennsylvania ( Site 6023)
Philadelphia, Pennsylvania, United States
Women & Infants Hospital ( Site 5003)
Providence, Rhode Island, United States
Texas Oncology - DFW ( Site 8004)
Fort Worth, Texas, United States
Texas Oncology-San Antonio Medical Center ( Site 8001)
San Antonio, Texas, United States
Texas Oncology - Northeast Texas ( Site 8002)
Tyler, Texas, United States
Inova Schar Cancer Institute ( Site 6003)
Fairfax, Virginia, United States
Instituto Alexander Fleming ( Site 0105)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0108)
Mar del Plata, Buenos Aires, Argentina
Fundación Respirar ( Site 0101)
Buenos Aires, Buenos Aires F.D., Argentina
Hospital Británico de Buenos Aires ( Site 0103)
CABA, , Argentina
Instituto San Marcos ( Site 0106)
San Juan, , Argentina
Blacktown Hospital ( Site 0201)
Blacktown, New South Wales, Australia
Royal Brisbane and Women's Hospital ( Site 0206)
Brisbane, Queensland, Australia
Epworth Freemasons ( Site 0207)
Melbourne, Victoria, Australia
Medizinische Universitaet Innsbruck-Univ.-Klinik f. Gynäkologie und Geburtshilfe ( Site 0301)
Innsbruck, Tyrol, Austria
Medizinische Universität Wien - Allg. Gynaekologie & Gyn. Onkologie ( Site 0302)
Vienna, , Austria
CHU Saint-Pierre ( Site 0405)
Brussels, Bruxelles-Capitale, Region de, Belgium
AZ Maria Middelares ( Site 0402)
Ghent, Oost-Vlaanderen, Belgium
UZ Leuven ( Site 0401)
Leuven, Vlaams-Brabant, Belgium
Grand Hôpital de Charleroi ( Site 0403)
Charleroi, Wallonne, Region, Belgium
CHU de Liege ( Site 0404)
Liège, Wallonne, Region, Belgium
Hospital Araújo Jorge ( Site 0521)
Goiânia, Goiás, Brazil
IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0525)
São Paulo, São Paulo, Brazil
Princess Margaret Cancer Center ( Site 0609)
Toronto, Ontario, Canada
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0605)
Montreal, Quebec, Canada
Jewish General Hospital ( Site 0606)
Montreal, Quebec, Canada
McGill University Health Centre ( Site 0604)
Montreal, Quebec, Canada
CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0608)
Sherbrooke, Quebec, Canada
Centro de Estudios Clínicos SAGA ( Site 0708)
Santiago, Region M. de Santiago, Chile
FALP ( Site 0702)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile ( Site 0705)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0703)
Santiago, Region M. de Santiago, Chile
ONCOCENTRO APYS ( Site 0704)
Viña del Mar, Región de Valparaíso, Chile
Peking University Peoples Hospital ( Site 0845)
Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital ( Site 0838)
Chongqing, Chongqing Municipality, China
Sun Yat-sen University Cancer Center ( Site 0846)
Guangzhou, Guangdong, China
Zhujiang Hospital of Southern Medical University ( Site 0829)
Guangzhou, Guangdong, China
Cancer Hospital of Shantou University Medical College ( Site 0827)
Shantou, Guangdong, China
Affiliated Hospital of Guangdong Medical University ( Site 0823)
Zhanjiang, Guangdong, China
Liuzhou People's Hospital ( Site 0831)
Liuzhou, Guangxi, China
Guangxi Medical University Affiliated Tumor Hospital. ( Site 0825)
Nanning, Guangxi, China
Wuhan Union Hospital Cancer Center ( Site 0824)
Wuhan, Hubei, China
Nanjing First Hospital ( Site 0828)
Nanjing, Jiangsu, China
Jiangxi Maternal and Child Health Hospital ( Site 0807)
Nanchang, Jiangxi, China
The First Hospital Of Jilin University ( Site 0815)
Changchun, Jilin, China
The First Affiliated Hospital of Xi'an Jiaotong University ( Site 0816)
Xi'an, Shaanxi, China
Shandong Cancer Hospital ( Site 0803)
Jinan, Shandong, China
Shanghai Tenth People's Hospital ( Site 0847)
Shanghai, Shanghai Municipality, China
Obstetrics & Gynecology Hospital of Fudan University ( Site 0818)
Shanghai, Shanghai Municipality, China
The Second People's Hospital of Yibin ( Site 0840)
Yibin, Sichuan, China
The Affiliated Women's Hospital of Zhejiang University ( Site 0834)
Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province ( Site 0809)
Linhai, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University ( Site 0805)
Wenzhou, Zhejiang, China
Instituto de Cancerología S.A.S ( Site 0904)
Medellín, Antioquia, Colombia
Fundacion Colombiana de Cancerología Clinica Vida ( Site 0905)
Medellín, Antioquia, Colombia
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0902)
Bogotá, Bogota D.C., Colombia
Oncologos Del Occidente ( Site 0907)
Pereira, Risaralda Department, Colombia
Nemocnice AGEL Novy Jicin a.s. ( Site 1102)
Nový Jičín, , Czechia
Vseobecna fakultni nemocnice v Praze-Gynekologicko-porodnicka klinika 1.LF a VFN ( Site 1101)
Prague, , Czechia
Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 1103)
Prague, , Czechia
Aarhus Universitetshospital, Skejby ( Site 1205)
Aarhus, Central Jutland, Denmark
Roskilde Sygehus ( Site 1204)
Roskilde, Region Sjælland, Denmark
Kuopion Yliopistollinen Sairaala ( Site 1304)
Kuopio, Northern Savonia, Finland
Tampereen yliopistollinen sairaala ( Site 1303)
Tampere, Pirkanmaa, Finland
Turku University Hospital-Department of Obstetrics and Gynecology ( Site 1302)
Turku, Southwest Finland, Finland
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 1301)
Helsinki, Uusimaa, Finland
Centre Francois Baclesse ( Site 1412)
Caen, Calvados, France
Hôpital Privé Des Côtes d'Armor ( Site 1404)
Plérin, Cotes-d Armor, France
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 1405)
Bordeaux, Gironde, France
Oncopole Claudius Regaud ( Site 1407)
Toulouse, Haute-Garonne, France
Institut Curie - site Saint-Cloud ( Site 1408)
Saint-Cloud, Hauts-de-Seine, France
CENTRE LEON BERARD ( Site 1401)
Lyon, Rhone, France
Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 1411)
Paris, , France
CaritasKlinikum Saarbrücken St. Theresia ( Site 1508)
Saarbrücken, Saarland, Germany
Alexandra General Hospital of Athens ( Site 1604)
Athens, Attica, Greece
Aretaieio Hospital ( Site 1602)
Athens, Attica, Greece
Agios Loukas Clinic-DEPARTMENT OF ONCOLOGY ( Site 1601)
Thessaloniki, Central Macedonia, Greece
Debreceni Egyetem Klinikai Kozpont-Szülészeti és Nőgyógyászati Klinika ( Site 1701)
Debrecen, , Hungary
Rambam Health Care Campus ( Site 2025)
Haifa, , Israel
Carmel Hospital ( Site 2023)
Haifa, , Israel
Shaare Zedek Medical Center ( Site 2020)
Jerusalem, , Israel
Sourasky Medical Center ( Site 2022)
Tel Aviv, , Israel
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 2107)
Meldola, Forli-Cesena, Italy
Ospedale Cannizzaro ( Site 2103)
Catania, , Italy
Azienda Ospedaliera Universitaria Careggi ( Site 2109)
Florence, , Italy
Istituto Europeo di Oncologia ( Site 2110)
Milan, , Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 2104)
Napoli, , Italy
Ehime University Hospital ( Site 2213)
Tōon, Ehime, Japan
Kurume University Hospital ( Site 2204)
Kurume, Fukuoka, Japan
Gunma Prefectural Cancer Center ( Site 2202)
Ōta, Gunma, Japan
National Hospital Organization Hokkaido Cancer Center ( Site 2212)
Sapporo, Hokkaido, Japan
Hyogo Cancer Center ( Site 2216)
Akashi, Hyōgo, Japan
Iwate Medical University Hospital ( Site 2207)
Shiwa-gun, Iwate, Japan
Saitama Medical University International Medical Center ( Site 2201)
Hidaka, Saitama, Japan
Cancer Institute Hospital of JFCR ( Site 2208)
Koto, Tokyo, Japan
Keio University Hospital ( Site 2209)
Shinjuku, Tokyo, Japan
National Hospital Organization Kyushu Cancer Center ( Site 2203)
Fukuoka, , Japan
Niigata Cancer Center Hospital ( Site 2210)
Niigata, , Japan
Okayama University Hospital ( Site 2215)
Okayama, , Japan
Stavanger Universitetssykehus ( Site 2703)
Norway, Rogaland, Norway
Universitetssykehuset Nord-Norge HF ( Site 2702)
Tromsø, Troms, Norway
Oslo universitetssykehus, Radiumhospitalet ( Site 2701)
Oslo, , Norway
Clínica San Felipe ( Site 2804)
Jesus Maria, Lima region, Peru
IPOR Instituto Peruano de Oncología & Radioterapia ( Site 2803)
San Isidro, Lima region, Peru
INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 2805)
Lima, , Peru
Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 3011)
Poznan, Greater Poland Voivodeship, Poland
Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie ( Site 3003)
Poznan, Greater Poland Voivodeship, Poland
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 3004)
Siedlce, Masovian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 3002)
Warsaw, Masovian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne-Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Gi ( Site 3001)
Gdansk, Pomeranian Voivodeship, Poland
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 3006)
Gliwice, Silesian Voivodeship, Poland
Swietokrzyskie Centrum Onkologii. ( Site 3008)
Kielce, Świętokrzyskie Voivodeship, Poland
Puerto Rico Cancer Specialists Clinical Trials ( Site 4201)
San Juan, , Puerto Rico
National University Hospital ( Site 3202)
Singapore, Central Singapore, Singapore
National Cancer Centre Singapore ( Site 3201)
Singapore, Central Singapore, Singapore
National Cancer Center ( Site 3106)
Gyeonggi-do, Kyonggi-do, South Korea
Keimyung University Dongsan Hospital ( Site 3105)
Daegu, Taegu-Kwangyokshi, South Korea
Seoul National University Hospital ( Site 3102)
Seoul, , South Korea
Severance Hospital, Yonsei University Health System ( Site 3101)
Seoul, , South Korea
Asan Medical Center ( Site 3103)
Seoul, , South Korea
Institut Català d'Oncologia - L'Hospitalet ( Site 3408)
L'Hospitalet de Llobregat, Barcelona, Spain
Institut Català d'Oncologia (ICO) - Girona ( Site 3407)
Girona, Gerona, Spain
Hospital Universitari Vall d''Hebron ( Site 3401)
Barcelona, , Spain
Hospital Universitario Reina Sofia ( Site 3402)
Córdoba, , Spain
Hospital Universitario Ramon y Cajal ( Site 3403)
Madrid, , Spain
Hospital Universitario 12 de Octubre ( Site 3404)
Madrid, , Spain
Fundación Instituto Valenciano de Oncología ( Site 3405)
Valencia, , Spain
Skånes Universitetssjukhus Lund ( Site 3502)
Lund, Skåne County, Sweden
Akademiska Sjukhuset ( Site 3501)
Uppsala, Uppsala County, Sweden
Taichung Veterans General Hospital ( Site 3703)
Taichung, , Taiwan
National Cheng Kung University Hospital ( Site 3702)
Tainan, , Taiwan
National Taiwan University Hospital ( Site 3701)
Taipei, , Taiwan
Mackay Memorial Hospital ( Site 3704)
Taipei, , Taiwan
Linkou Chang Gung Memorial Hospital ( Site 3705)
Taoyuan District, , Taiwan
Ramathibodi Hospital. ( Site 3802)
Bangkok, Bangkok, Thailand
Faculty of Medicine Siriraj Hospital ( Site 3801)
Bangkok, Bangkok, Thailand
Maharaj Nakorn Chiang Mai Hospital ( Site 3804)
Chiang Mai, , Thailand
Faculty of Medicine - Khon Kaen University ( Site 3803)
Khon Kaen, , Thailand
University Hospitals Sussex NHS Foundation Trust ( Site 4011)
East Sussex, Brighton And Hove, United Kingdom
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 4006)
London, London, City of, United Kingdom
Hammersmith Hospital ( Site 4010)
London, London, City of, United Kingdom
Western General Hospital ( Site 4012)
Edinburgh, Midlothian, United Kingdom
Royal Marsden Hospital (Sutton) ( Site 4005)
London, Surrey, United Kingdom
The Christie NHS Foundation Trust ( Site 4003)
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-519331-42-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1315-0794
Identifier Type: REGISTRY
Identifier Source: secondary_id
GOG-3119
Identifier Type: OTHER
Identifier Source: secondary_id
ENGOT-en29
Identifier Type: OTHER
Identifier Source: secondary_id
TroFuse-033
Identifier Type: OTHER
Identifier Source: secondary_id
jRCT2011250020
Identifier Type: REGISTRY
Identifier Source: secondary_id
2870-033
Identifier Type: -
Identifier Source: org_study_id